Pro Share Advisors LLC Y M Abs Therapeutics, Inc. Transaction History

Pro Share Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	SELL	$8.22 - $15.13 $90,987 - $167,473	-11,069 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$6.55 - $17.42 $17,750 - $47,208	-2,710 Reduced 19.67%	11,069 $132,000
Q4 2021 Feb 08, 2022	SELL	$15.51 - $29.31 $124 - $234	-8 Reduced 0.06%	13,779 $224,000
Q3 2021 Nov 12, 2021	SELL	$27.47 - $37.31 $85,349 - $115,922	-3,107 Reduced 18.39%	13,787 $393,000
Q2 2021 Aug 13, 2021	BUY	$25.45 - $37.64 $69,325 - $102,531	2,724 Added 19.22%	16,894 $571,000
Q1 2021 May 14, 2021	BUY	$29.16 - $51.96 $33,767 - $60,169	1,158 Added 8.9%	14,170 $429,000
Q4 2020 Feb 09, 2021	BUY	$37.86 - $54.26 $109,566 - $157,028	2,894 Added 28.6%	13,012 $644,000
Q3 2020 Nov 13, 2020	SELL	$35.13 - $43.62 $10,714 - $13,304	-305 Reduced 2.93%	10,118 $388,000
Q2 2020 Aug 03, 2020	BUY	$23.66 - $49.53 $246,608 - $516,251	10,423 New	10,423 $450,000
Q1 2020 May 15, 2020	SELL	$14.39 - $35.8 $169,730 - $422,260	-11,795 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$23.81 - $33.78 $280,838 - $398,435	11,795 New	11,795 $369,000

106

24.5M

40.3K

400

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $487M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Pro Share Advisors LLC with notifications on news.